Projects
Provide a general description of the items below and introduce the services you offer. Click on the text box to edit the content.
Maternal Immunization
Describe your service here. What makes it great? Use short catchy text to tell people what you offer, and the benefits they will receive. A great description gets readers in the mood, and makes them more likely to go ahead and book.
Tumor Infiltrating B cells (TIL-B)
Describe your service here. What makes it great? Use short catchy text to tell people what you offer, and the benefits they will receive. A great description gets readers in the mood, and makes them more likely to go ahead and book.
Anti-Bacterial Immunotherapy
Describe your service here. What makes it great? Use short catchy text to tell people what you offer, and the benefits they will receive. A great description gets readers in the mood, and makes them more likely to go ahead and book.
Maternal Immunization
Many vaccine-preventable diseases, like influenza, pertussis, and tetanus cause substantial morbidity and mortality in pregnant women, newborns and infants. Immunization during pregnancy has the potential to provide protection to the newborn and infant by the transplacental transfer of vaccine-specific maternal antibodies. However, the immunobiology underlying immunization during pregnancy, that leads to the protection of the newborn are not understood. Current vaccine formulations were designed for and tested in non-pregnant populations; yet substantial immune modulations take place during different stages of pregnancy and potentially can impact the humoral response following maternal immunzation. We thus have insufficient data on quantity and quality of the immune response during pregnancy and how this relates to immunity provided from the mother to the newborn. First, we hypothesize that the nature and breadth of the humoral immune response following vaccination differs in pregnant and non-pregnant vaccinees. Next, we hypothesize that the vaccine-specific antibodies that cross the plaecenta, comprise distinct repertoire features thus, the placenta functions as a differential barrier for antibody transfer. To test these hypotheses, we use proteomic and genomic/transcriptomic measurements of antibody repertoires in the maternal and cord blood compartments. The measurements will be based on antibody clonal diversity/frequency, V(D) J gene germline usage and SHM, where we expect to find changes in i) vaccine-specific B cell frequency, antibody clonal diversity, germline usage and SHM in pregnant women and ii) distinct repertoire features in the transplacental vaccine-specific antibody compartment compared the maternal compartment. We will utilize deep sequencing and proteomic technologies to provide, for the first time, insight into the immunobiology of a promising intervention aimed to prevent early life infectious morbidity and mortality and establish new research avenues for vaccine research in vulnerable populations.
Anti-Bacterial Immunotherapy
The emergence of MDR bacterial strains, especially those of pathogenic bacteria, has very serious medical and clinical implications, and is a growing public health concern worldwide. In high-income countries where antibiotics are heavily used in the community and agriculture, the strong selection pressure and non-completed antibiotic regimens have resulted in the emergence and dominance of MDR strains, forcing a shift to more expensive and broad-spectrum antibiotics.
Development of new MAbs for pharmaceutical development has increased substantially during the recent years. One major unmet need is the development of new antibacterial MAbs as alternatives to antibiotics, especially in light of the emergence of MDR bacteria. Recent developments and accumulated data are converging to turn antibacterial MAbs into powerful therapeutics for fighting infections. Anti-bacterial MAbs offer key benefits over conventional antibiotics. a) Unlike antibiotics, they do not provide selection pressure feedback to the genome, hence are less likely to induce resistance among bacteria.
b) MAbs are designed against bacterial pathogen targets and thus should not perturb the nonpathogenic microbiota which lack the target. c) The MAb can be injected as a single-dose regimen when urgently needed, or concomitantly with traditional antibiotics, which could have synergistic bacteria-clearing effects. This project aims to provide a novel therapeutic monoclonal antibody (MAb) to treat infections by multidrug-resistant (MDR) pathogenic bacteria. Specific aims:
(i)To establish the molecular mechanism of action (MoA) of the MAb including the cell biology underlining its inhibitory mechanism in an ex-vivo bacterial model system.
(ii)To advance the MAb to the stage of development and clinical trials.
Tumor Infiltrating B cells (TIL-B)
Currently, tumor-infiltrating B cells (TIL-B) have been recognized as a new hallmark of several types of cancers. The function seems to be controversial, either with positive, negative, or no significance in the prediction and prognosis. Moreover, B-cell infiltrates regulate tumor process through productions of antibodies. The interactions with other lymphocytes and programmed death-1/PD-1 ligand axis is also documented. However, B cells infiltrating into solid tumors are poorly investigated. Whether their potential as antitumor comes from either the antigen presentation or the antibody production capacity or both, is unknown.
In this project, we aim to investigate the role of B cells in the tumor microenvironment and shed light on the mechanisms involved in their anti-tumor activity. We utilize NGS and RNA-seq to profile the TIL-B and aim to shed light on their potential leads for the development of new therapeutic strategies.